EA Pharma Co. Ltd. has described 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors reported to be useful for the treatment of age-related issues, as well as inflammatory, metabolic, neurodegenerative, mitochondrial and renal diseases.
Evotec International GmbH has synthesized integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.
Kalvista Pharmaceuticals Ltd. has identified coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of hereditary angioedema, atherosclerosis, inflammatory disorders, neurodegeneration, diabetic retinopathy, SARS-CoV-2 infection (COVID-19), stroke and thrombotic disorders, among others.
MDX-2001 (Modex Therapeutics Inc.) was engineered as a potentially first-in-class tetraspecific lymphocyte activator and survival enhancement receptor (LASER) recognizing CD3 and CD28 on human T cells and c-MET and TROP2 on tumor cells.
DEAD-box helicase 17 (DDX17) is an RNA helicase involved in the early phases of neuronal differentiation. Researchers have identified a total of 13 patients presenting with neurodevelopmental phenotypes and who harbored de novo monoallelic variants in the DDX17 gene. The phenotype was characterized by intellectual disability, delayed speech and language, as well as motor delay.
Genetic alterations in FAT1, YAP1 or WWTR1 genes are commonly seen in head and neck squamous cell carcinoma (HNSCC) patients. Targeting Hippo and MAPK pathways in combination has proven effective in preclinical models of HNSCC.
Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have signed a new collaboration and option agreement to develop ND-081, a multispecific antibody for the treatment of inflammatory bowel disease.
RSS
